Last reviewed · How we verify
Botulinum toxin A (Botox A®)
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Overactive bladder with urge incontinence (pelvic floor disorders), Muscle spasticity, Chronic migraine.
At a glance
| Generic name | Botulinum toxin A (Botox A®) |
|---|---|
| Also known as | (Botox A®) |
| Sponsor | NICHD Pelvic Floor Disorders Network |
| Drug class | Neurotoxin; Acetylcholine release inhibitor |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Urology; Pain Management |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE proteins (specifically SNAP-25) required for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission, resulting in flaccid paralysis of the injected muscle. The effect is temporary, lasting 3-4 months, as the body gradually regenerates new nerve terminals.
Approved indications
- Overactive bladder with urge incontinence (pelvic floor disorders)
- Muscle spasticity
- Chronic migraine
- Cervical dystonia
- Blepharospasm
Common side effects
- Urinary retention
- Urinary tract infection
- Incomplete bladder emptying
- Dysuria
- Muscle weakness (at injection site)
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial (PHASE4)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin A (Botox A®) CI brief — competitive landscape report
- Botulinum toxin A (Botox A®) updates RSS · CI watch RSS
- NICHD Pelvic Floor Disorders Network portfolio CI